Personalized Cancer Therapy
The goal of this study is to perform standardized testing to determine which different genes are mutated (have gone through changes) in cancer patients to provide them with personalized cancer therapy. A patient's doctor may be able to use testing information on their tumor to identify clinical trials that may be most relevant to them.
Another goal of this laboratory research study is to learn how often different genes mutate in patients with different cancers. Researchers will also use the information learned from this study to develop a database of the different kinds of mutations in cancer-related genes.
Researchers also hope to better understand how mutations in cancer-related genes may affect a patient's response to different therapies. Researchers can use this information to select specific therapies for future patients that are more likely to be effective.
|Study Design:||Observational Model: Case-Only
Time Perspective: Prospective
|Official Title:||Molecular Testing for the MD Anderson Cancer Center Personalized Cancer Therapy Program|
- Database of Somatic Mutations and Clinical Characteristics [ Time Frame: 20 years ] [ Designated as safety issue: No ]Collection and storage of tumor tissue specimens, blood and/or saliva samples of patients with cancer for somatic mutation analysis for assessing patients that may be eligible for new targeted therapy trials.
Biospecimen Retention: Samples With DNA
Blood drawn once during a scheduled visit. Buccal swab or saliva sample may be collected during a scheduled visit for patients with hematologic or other disease.
|Study Start Date:||March 2012|
|Estimated Primary Completion Date:||March 2032 (Final data collection date for primary outcome measure)|
Patients with histologically or cytologically documented invasive cancer, sarcoma, or hematologic cancer
Information about patients/participants' diseases and previous and future treatments and outcomes will be recorded from medical records. A sample of tumor tissue that was already collected and stored at MD Anderson or another institution will be collected. Blood (about 4 teaspoons) will be drawn so that researchers have a sample of normal cells to use for comparison to cancer cells, a saliva sample or a cheek cell sample may be collected instead of the blood sample.
The MD Anderson Cancer Center Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy (IPCT) is committed to implementing personalized cancer therapy for all patients coming to MD Anderson, transforming cancer patient management and improving outcomes by making this approach the new standard of care. The ultimate goal is to perform in-depth molecular characterization of all tumors, in order to tailor therapies offered and identify best standard of care and clinical trial options.
|Contact: Funda Meric-Bernstam, MD||713-792-6940|
|United States, Texas|
|UT MDACC/Regional Cancer Centers||Recruiting|
|Houston, Texas, United States, 77030|
|Principal Investigator: Funda Meric-Bernstam, MD|
|Study Chair:||Funda Meric-Bernstam, MD||UT MD Anderson Cancer Center|